Nanobiotix Newswire

Nanobiotix Newswire

Comprehensive Real-Time News Feed for Nanobiotix.

Results 1 - 20 of 25 in Nanobiotix

  1. Press release: Nanobiotix starts a new research program, in Immuno...Read the original story

    Jan 8, 2016 | Nanotechweb.org

    NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology. Elsa Borghi, Nanobiotix's Medical Director, commented: "With six ongoing indications, our global clinical development of NBTXR3 as a radio-enhancer, is progressing well.

    Comment?

  2. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Jan 7, 2016 | Business Wire

    ... Osteoporosis - Pipeline Review, ... )--Regulatory News: Au titre du contrat de liquidite confie par la Societe NANOBIOTIX (Paris:NANO) a la Societe de Bourse Gilbert Dupont, a la date du 31 decembre 2015, les moy... )--IBC is delighted to announce ...

    Comment?

  3. Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market Is...Read the original story w/Photo

    Jan 6, 2016 | SBWire

    ... Eckert & Ziegler BEBIG, EmboMedics, Inc., Kobo Products, Inc., Merit Medical Systems, Inc., Mo-Sci Corporation, Nanobiotix, Polysciences, Inc., Sirtex Medical, Inc. and Terumo Medical Corporation. Request a Free Sample Copy of the Report @ ...

    Comment?

  4. Nanobiotix Starts A New Research Program, In Immuno Oncology, With Its Lead Product NBTXR3Read the original story

    Jan 4, 2016 | BioSpace

    Paris, Cambridge, January 5, 2016 - NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology. Elsa Borghi, Nanobiotix's Medical Director, commented: "With six ongoing indications, our global clinical development of NBTXR3 as a radio-enhancer, is progressing well.

    Comment?

  5. Nanobiotix Release: FDA Approved Investigational New Drug For NBTXR3...Read the original story

    Jan 3, 2016 | BioSpace

    Paris France, Cambridge MA, USA, January 4th, 2016 - NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the US Food and Drug Administration has approved the Company's Investigational New Drug application on the 30th of December. This allows Nanobiotix to launch its first clinical study in the US for its lead product NBTXR3 in prostate cancer, a new and very significant indication.

    Comment?

  6. FDA approved investigational new drug for NBTXR3 in a new clinical study in prostate cancerRead the original story w/Photo

    Jan 4, 2016 | Medical News Today

    NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer , announces the US Food and Drug Administration has approved the Company's Investigational New Drug application on the 30th of December. This allows Nanobiotix to launch its first clinical study in the US for its lead product NBTXR3 in prostate cancer , a new and very significant indication.

    Comment?

  7. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Nov 13, 2015 | Business Wire

    ... seventh annual Give to the Max Day, a 24-hour online give-a-thon. More than 62,000 pe... )--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO - ISIN: FR0011341205), sociA tA franA aise pionniA re en nanomA decine ...

    Comment?

  8. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Nov 13, 2015 | Business Wire

    ... seventh annual Give to the Max Day, a 24-hour online give-a-thon. More than 62,000 pe... )--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO - ISIN: FR0011341205), sociA tA franA aise pionniA re en nanomA decine ...

    Comment?

  9. Nanobiotix Revenue for Q3 2015Read the original story

    Nov 13, 2015 | Business Wire

    NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its unaudited revenue for the third quarter of 2015. Nanobiotix's revenue during Q3 2015 corresponds to the upfront payment received by the Company from Taiwan-based PharmaEngine, within the framework of the licensing contract signed in August 2012 for the development and commercialization of the lead NanoXray product, NBTXR3 in the Asia-Pacific region.

    Comment?

  10. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Oct 6, 2015 | Business Wire

    ... Service designation, which recognizes Premium Hosting Partners who provide an exceptional ... )--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO - ISIN: FR0011341205), sociA tA franA aise pionniA re en nanomA decine ...

    Comment?

  11. New Market Research Report: Rectal Cancer - Pipeline Review, H2 2015Read the original story w/Photo

    Sep 22, 2015 | PR-inside.com

    ... AbbVie Inc., Cerulean Pharma, Inc., Hanwha Chemical Corporation, Incuron, LLC, Karyopharm Therapeutics, Inc., Nanobiotix, Peregrine Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Synta Pharmaceuticals Corp. About Global Markets Direct ...

    Comment?

  12. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Aug 27, 2015 | Business Wire

    The company is committed to offering healthy and natura... )--Canon U.S.A., a leader in digital imaging solutions, today announced that Graphistudio, an Italian-based wedding photography printer with a name long associated wit... )--The Board of Directors of Myriant Corporation , an affiliate of PTT Global Chemical Public Company Limited , today announced that Cenan Ozmeral, ... )--Regulatory News: NANOBIOTIX , sociA tA franA aise pionniA re en nanomA decine dA veloppant NanoXray, une approche thA rapeutique... )--Regulatory News: NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatmen... )--Arizona Center for Civic Leadership, a program of the Flinn Foundation of Phoenix, announces its 2015 Flinn-Brown Academy Fellows.

    Comment?

  13. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Aug 27, 2015 | Business Wire

    )--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO - ISIN: FR0011341205), sociA tA franA aise pionniA re en nanomA decine dA veloppant NanoXray, une approche thA rapeutique... )--Regulatory News: NANOBIOTIX ...

    Comment?

  14. New Report Available: PharmaEngine, Inc. (4162) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Jul 28, 2015 | PR-inside.com

    ... the treatment of metastatic pancreatic cancer. The company is partnered with Merrimack Pharmaceuticals, Inc., and Nanobiotix S.A. It has research and development facility. The company has collaboration with Guangzhou BeBetter Medicine Technology ...

    Comment?

  15. Soft Tissue Sarcoma Therapeutic Assessment Pipeline Review H1 2015Read the original story

    Jul 22, 2015 | Emailwire.com

    ... Merck & Co., Inc., Merrimack Pharmaceuticals, Inc., Mirati Therapeutics Inc., MolMed S.p.A., Morphotek, Inc., Nanobiotix, Neotropix, Inc., Novartis AG, Oncos Therapeutics Ltd., Onxeo SA, Pfizer Inc., Pharma Mar, S.A., Plexxikon Inc., Polaris ...

    Comment?

  16. Nanobiotix Revenue For Q2 2015Read the original story

    Jul 14, 2015 | BioSpace

    Paris, France, July 15, 2015 - NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2015. Income statement Activity NANOBIOTIX's revenue during the second quarter of 2015 corresponds to the upfront payment received by the company from Taiwan-based PharmaEngine, within the framework of the licensing contract signed in August 2012 for the development and commercialization of the lead product, NBTXR3 in the Asia-Pacific region.

    Comment?

  17. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Jul 8, 2015 | Business Wire

    ... ETF DEALING DATE 07-Jul-15 NAV PER SHARE USD45.6305 NUMBER OF SHARES IN ISSUE 46,288,979 CODE )--Regulatory News: Nanobiotix (Paris:NANO): Place de cotation : Euronext Paris de Nyse Euronext Compartiment : Compartiment B Code ISIN : FR0011341205 ...

    Comment?

  18. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Jul 2, 2015 | Business Wire

    ... MTN ISSUE NAME. Our Ref. MJ3275 ISIN Code. XS1241577060 INTEREST AMT PER DENOM. CURRENCY ... )--Regulatory News: Nanobiotix (Paris:NANO): Au titre du contrat de liquidite confie par la societe NANOBIOTIX a la Societe de Bourse Gilbert Dupont, a la ...

    Comment?

  19. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Jul 2, 2015 | Business Wire

    ... MTN ISSUE NAME. Our Ref. MJ3275 ISIN Code. XS1241577060 INTEREST AMT PER DENOM. CURRENCY ... )--Regulatory News: Nanobiotix (Paris:NANO): Au titre du contrat de liquidite confie par la societe NANOBIOTIX a la Societe de Bourse Gilbert Dupont, a la ...

    Comment?

  20. The Drums Of BIO 2015: Dollars, Nano and DataRead the original story w/Photo

    Jul 2, 2015 | Pharmaceutical Online

    ... formulated with surfactants that mediate non-covalent binding of antibodies and other biological molecules. Nanobiotix's product in phase three NBTXR3 is another application of nano that could dramatically help patients. The product consists of ...

    Comment?